DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Joint Meeting of the
National Center for Advancing Translational Sciences Advisory Council
(8th Meeting) and Cures Acceleration Network Review Board (10th Meeting)
January 15, 2015
8:30 a.m. - 5:00 p.m.
Building 31C, 6th Floor, Conference Room 6
Bethesda, Maryland 20892

Future Advisory Council & CAN Review Board Joint Meetings

<table>
<thead>
<tr>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 17-18</td>
<td>January 14-15</td>
</tr>
<tr>
<td>September 3-4</td>
<td>May 12-13</td>
</tr>
<tr>
<td></td>
<td>September 15-16</td>
</tr>
</tbody>
</table>

Future CAN Review Board (only) Meetings (by phone)

<table>
<thead>
<tr>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 11</td>
<td>December 8</td>
</tr>
</tbody>
</table>

Agenda – OPEN SESSION

Open Session of the meeting will be webcast. To view, please go to: http://videocast.nih.gov/summary.asp?live=15419

8:30 - 8:50 a.m. Call to Order, Open Session
Christopher P. Austin, M.D., Director, NCATS; Chairperson - Advisory Council
Freda C. Lewis-Hall, M.D., Chief Medical Officer, Pfizer; Chairperson - CAN Review Board

8:50 - 9:00 a.m. Approval of Minutes from September 2014 Joint Meeting

Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings
Danilo A. Tagle, Ph.D., M.S., Executive Secretary, NCATS Advisory Council

Introduction of New Staff
9:00 - 10:00 a.m.  NCATS Director’s Report
Christopher P. Austin, M.D., Director, NCATS
Discussion

10:00 - 10:30 a.m.  BREAK

10:30 - 11:30 a.m.  Overview of Rare Diseases Clinical Research Network
Pamela M. McInnes, D.D.S., M.Sc.(Dent.), Deputy Director, and Acting Director of Office of Rare Diseases Research, NCATS

The Transformation of Clinical Research in Vasculitis Through the Rare Diseases Clinical Research Network
Peter A. Merkel, M.D., M.P.H., Professor of Medicine and Epidemiology, Chief of Rheumatology, University of Pennsylvania

Perspective from an RDCRN Consortium’s PAG as Research Partner
Michele Manion, B.S., Vice President, Executive Director, Founder, Primary Ciliary Dyskinesia Foundation
Discussion

11:30 a.m. - Noon  Report from Council Subcommittee

Medical Technologies (Devices and Diagnostics)
Frank L. Douglas, Ph.D., M.D., President and CEO, Austen Bioinnovation Institute in Akron
Discussion

Noon - 1:00 p.m.  LUNCH

1:00 - 2:00 p.m.  CTSA Update
Petra Kaufmann, M.D., M.Sc., Director, Division of Clinical Innovation, NCATS
Discussion

2:00 - 3:00 p.m.  Council and CAN RB-Initiated Discussion
Advisory Council and CAN Review Board Members
Discussion

3:00 p.m.  Adjourn, Open Session
3:15 - 5:00 p.m.  

**Closed Session**  
This portion of the meeting is closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

**Review of Conflict of Interest, Confidentiality and Council Procedures**  
Danilo A. Tagle, Ph.D., M.S., Executive Secretary, NCATS Advisory Council and CAN Review Board

**Council Consideration of Pending Applications**  
Danilo A. Tagle, Ph.D., M.S., Executive Secretary, NCATS Advisory Council and CAN Review Board